神奇制药
(600613)
| 流通市值：26.03亿 | | | 总市值：29.00亿 |
| 流通股本：4.79亿 | | | 总股本：5.34亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 422,940,454.91 | 1,952,370,316.93 | 1,397,861,990.39 | 960,849,846.72 |
| 营业收入 | 422,940,454.91 | 1,952,370,316.93 | 1,397,861,990.39 | 960,849,846.72 |
| 二、营业总成本 | 397,839,294.39 | 1,850,971,624.35 | 1,317,761,316.36 | 903,529,215.25 |
| 营业成本 | 232,061,558.04 | 1,071,682,276.02 | 740,077,387.15 | 510,774,959.81 |
| 税金及附加 | 10,040,057.47 | 27,232,413.01 | 22,409,618.58 | 14,474,919.24 |
| 销售费用 | 124,139,222.1 | 619,133,130.61 | 462,198,005.49 | 317,994,848.64 |
| 管理费用 | 23,884,145.33 | 99,573,344.71 | 69,824,726.88 | 44,994,683.6 |
| 研发费用 | 7,038,684.07 | 30,239,194.87 | 21,761,826.84 | 13,850,931.65 |
| 财务费用 | 675,627.38 | 3,111,265.13 | 1,489,751.42 | 1,438,872.31 |
| 其中:利息费用 | 2,374,189.41 | 10,071,064.98 | 6,973,028.75 | 5,104,956.55 |
| 其中:利息收入 | 1,838,638.81 | 7,438,646.67 | 6,351,502.62 | 4,097,106.48 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 724,243.63 | 548,844.96 | 1,013,050.21 | 151,126.36 |
| 加:投资收益 | 230,140.38 | 2,994,678.83 | - | - |
| 资产处置收益 | - | 227,956.19 | 30,295.83 | - |
| 资产减值损失(新) | -1,266,441.83 | -16,348,367.9 | -12,603,522.78 | -8,017,259.23 |
| 信用减值损失(新) | -4,093,059.49 | -21,264,639.42 | -6,118,676.12 | -5,968,578.48 |
| 其他收益 | 409,008.29 | 6,257,806.54 | 3,837,393.98 | 2,651,717.94 |
| 四、营业利润 | 21,105,051.5 | 73,814,971.78 | 66,259,215.15 | 46,137,638.06 |
| 加:营业外收入 | 91,322.26 | 234,692.15 | 117,178.13 | 70,005.42 |
| 减:营业外支出 | 1,789,992.33 | 3,177,147.94 | 1,218,606.11 | 752,919.55 |
| 五、利润总额 | 19,406,381.43 | 70,872,515.99 | 65,157,787.17 | 45,454,723.93 |
| 减:所得税费用 | 7,379,340.68 | 31,037,431.25 | 14,066,768.33 | 11,040,218.48 |
| 六、净利润 | 12,027,040.75 | 39,835,084.74 | 51,091,018.84 | 34,414,505.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,027,040.75 | 39,835,084.74 | 51,091,018.84 | 34,414,505.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 12,884,205.7 | 38,244,070.55 | 50,301,604.35 | 32,808,146.86 |
| 少数股东损益 | -857,164.95 | 1,591,014.19 | 789,414.49 | 1,606,358.59 |
| 扣除非经常损益后的净利润 | 12,677,189.66 | 34,868,994.82 | 47,215,038.02 | 31,976,889.64 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.07 | 0.09 | 0.06 |
| (二)稀释每股收益 | 0.02 | 0.07 | 0.09 | 0.06 |
| 八、其他综合收益 | -6,176,733.03 | -838,779.31 | -223,221.11 | -3,417,692.18 |
| 归属于母公司股东的其他综合收益 | -6,176,733.03 | -838,779.31 | -223,221.11 | -3,417,692.18 |
| 九、综合收益总额 | 5,850,307.72 | 38,996,305.43 | 50,867,797.73 | 30,996,813.27 |
| 归属于母公司股东的综合收益总额 | 6,707,472.67 | 37,405,291.24 | 50,078,383.24 | 29,390,454.68 |
| 归属于少数股东的综合收益总额 | -857,164.95 | 1,591,014.19 | 789,414.49 | 1,606,358.59 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |